TY - JOUR
T1 - Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients
AU - Hooshmand, Farnaz
AU - Do, Dennis
AU - Shah, Saloni
AU - Gershon, Anda
AU - Park, Dong Yeon
AU - Kim, Hyun
AU - Yuen, Laura D.
AU - Dell'Osso, Bernardo
AU - Wang, Po W.
AU - Ketter, Terence A.
AU - Miller, Shefali
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Aims: Antidepressant use is controversial in bipolar disorder (BD) due to questionable efficacy/psychiatric tolerability. We assessed demographic/clinical characteristics of baseline antidepressant use in BD patients. Methods: Prevalence and correlates of baseline antidepressant use in 503 BD I and BD II outpatients referred to the Stanford Bipolar Clinic during 2000–2011 were assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation. Results: Antidepressant use was 39.0%, overall, and was higher in BD II versus BD I (46.9% versus 30.5%, p = 0.0002). Both BD I and BD II antidepressant compared to non-antidepressant users had higher rates of complex pharmacotherapy (≥ 4 mood stabilizers, antipsychotics, and/or antidepressants) and use of other psychotropics. Antidepressant use in BD II versus BD I was higher during euthymia (44.0% vs. 28.0%) and subsyndromal symptoms (56.1% vs. 28.6%), but not depression or mood elevation. Limitations: American tertiary BD clinic referral sample receiving open naturalistic treatment. Conclusions: In our sample, antidepressant use was higher in BD II versus BD I patients, and was associated with markers of heightened illness severity in both BD I and BD II patients. Additional research is warranted to investigate these complex relationships.
AB - Aims: Antidepressant use is controversial in bipolar disorder (BD) due to questionable efficacy/psychiatric tolerability. We assessed demographic/clinical characteristics of baseline antidepressant use in BD patients. Methods: Prevalence and correlates of baseline antidepressant use in 503 BD I and BD II outpatients referred to the Stanford Bipolar Clinic during 2000–2011 were assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation. Results: Antidepressant use was 39.0%, overall, and was higher in BD II versus BD I (46.9% versus 30.5%, p = 0.0002). Both BD I and BD II antidepressant compared to non-antidepressant users had higher rates of complex pharmacotherapy (≥ 4 mood stabilizers, antipsychotics, and/or antidepressants) and use of other psychotropics. Antidepressant use in BD II versus BD I was higher during euthymia (44.0% vs. 28.0%) and subsyndromal symptoms (56.1% vs. 28.6%), but not depression or mood elevation. Limitations: American tertiary BD clinic referral sample receiving open naturalistic treatment. Conclusions: In our sample, antidepressant use was higher in BD II versus BD I patients, and was associated with markers of heightened illness severity in both BD I and BD II patients. Additional research is warranted to investigate these complex relationships.
KW - Antidepressant
KW - Bipolar disorder
KW - Illness characteristics
UR - http://www.scopus.com/inward/record.url?scp=85042879416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042879416&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.02.091
DO - 10.1016/j.jad.2018.02.091
M3 - Article
AN - SCOPUS:85042879416
VL - 234
SP - 74
EP - 79
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
ER -